EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Genomics in atrial fibrillation: Predicting recurrence of AF after treatment using genetics

Samuel Harwood, M Benjamin Shoemaker, John Barnard, David R Van Wagoner, Daniel P Morin, Mina K Chung

Progress in Cardiovascular Diseases · 2025

DOI: 10.1016/j.pcad.2025.06.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2025. Verfasst von Samuel Harwood und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States of America. Hauptthemen laut MEDLINE: Atrial Fibrillation, Genomics, Anti-Arrhythmia Agents, Genetic Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: American Heart Association, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the demonstration that AF is highly hereditable and strongly associated with over 100 genetic loci, one step towards personalized treatment of AF is the potential use of genetic testing to predict response to therapy. Although various clinical models have been developed to predict recurrence, none have shown a consistent ability to predict treatment outcomes. This highlights a need for additional patient information to increase predictive value. Here, we review the use of genetic data for prediction of AF recurrence after interventions such as ablation, cardioversion, or drug therapy. We explore the use of other downstream predictors, such as mRNA and protein, as other possible predictive tools. Finally, we assess how this genetic data can further our mechanistc understanding of AF pathogenesis and recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationGenomicsAnti-Arrhythmia AgentsGenetic TestingHumansRecurrenceGenetic Predisposition to DiseasePredictive Value of TestsTreatment OutcomeRisk FactorsPhenotypeCatheter AblationPrecision MedicineRisk AssessmentElectric Countershock

Stichwörter der Autor:innen

AblationAblatogenomicsAtrial fibrillationPITX2

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States of America.
  • Vanderbilt University School of Medicine, Nashville, TN, United States of America.
  • Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America.
  • The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States of America; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America.
  • University of San Francisco, San Francisco, CA.
  • The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States of America; Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States of America; Heart, V…

Förderung

  • American Heart Association
  • National Institutes of Health

Zitieren

APA

Harwood, S., Shoemaker, M. B., Barnard, J., Van Wagoner, D. R., Morin, D. P., & Chung, M. K. (2025). Genomics in atrial fibrillation: Predicting recurrence of AF after treatment using genetics. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2025.06.008

Vancouver

Harwood S, Shoemaker MB, Barnard J, Van Wagoner DR, Morin DP, Chung MK. Genomics in atrial fibrillation: Predicting recurrence of AF after treatment using genetics. Progress in Cardiovascular Diseases. 2025. doi:10.1016/j.pcad.2025.06.008

BibTeX
@article{Harwood2025,
  author = {Harwood, Samuel and Shoemaker, M Benjamin and Barnard, John and Van Wagoner, David R and Morin, Daniel P and Chung, Mina K},
  title = {Genomics in atrial fibrillation: Predicting recurrence of AF after treatment using genetics},
  journal = {Progress in Cardiovascular Diseases},
  year = {2025},
  doi = {10.1016/j.pcad.2025.06.008}
}
Kostenlos starten →